Antibiotic overuse and resistance in dermatology

Dermatologic Therapy

Volumn 25, Issue 1, 2012, Pages 55-69

  Chon, Susan Y ^a   Doan, Hung Q ^c   Mays, Rana Majd ^d   Singh, Selina M ^b   Gordon, Rachel A ^d   Tyring, Stephen K ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d Center for Clinical Studies   (United States)

Author keywords

antibiotic; dermatology; resistance

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BENZOYL PEROXIDE; CEFALEXIN; CEFOTAXIME; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; DICLOXACILLIN; DOXYCYCLINE; ERTAPENEM; ERYTHROMYCIN; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; FLUCLOXACILLIN; FUSIDIC ACID; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; MINOCYCLINE; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PSEUDOMONIC ACID; RETAPAMULIN; RIFAMPICIN; SULFAMETHOXAZOLE; TETRACYCLINE; TRIMETHOPRIM;

ACNE VULGARIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; CELLULITIS; CHLAMYDIA; CHLAMYDIACEAE INFECTION; DERMATOLOGY; DRUG USE; ECTHYMA; ERYSIPELAS; FOLLICULITIS; GONORRHEA; HUMAN; IMPETIGO; LONG TERM CARE; MEDICAL PRACTICE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NECROTIZING FASCIITIS; NONHUMAN; PROPIONIBACTERIUM ACNES; ROSACEA; SKIN TUBERCULOSIS; STAPHYLOCOCCAL SCALDED SKIN SYNDROME; STREPTOCOCCUS PYOGENES; STREPTOMYCES AUREOFACIENS; SYPHILIS; TREATMENT RESPONSE; ULCUS MOLLE;

ANTI-BACTERIAL AGENTS; DERMATOLOGY; DRUG RESISTANCE, BACTERIAL; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; SKIN DISEASES;

EID: 84861317594     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2012.01520.x     Document Type: Article

References (146)

1. Cooper AJ,. Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Med J Aust 1998: 169 (5): 259-261.
2. Ross JI, Snelling AM, Carnegie E, et al,. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol 2003: 148 (3): 467-478.
3. Fanelli M, Kupperman E, Lautenbach E, Edelstein PH, Margolis DJ,. Antibiotics, acne, and Staphylococcus aureus colonization. Arch Dermatol 2011: 147 (8): 917-921.
4. Levy RM, Huang EY, Roling D, Leyden JJ, Margolis DJ,. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch Dermatol 2003: 139 (4): 467-471.
5. Nishijima S, Namura S, Kawai S, Akamatsu H, Asada Y, Kawabata S,. Sensitivity of Staphylococcus aureus and Streptococcus pyogenes isolated from skin infections in 1992 to antimicrobial agents. J Dermatol 1994: 21 (4): 233-238.
6. Ochsendorf F,. Systemic antibiotic therapy of acne vulgaris. J Dtsch Dermatol Ges 2006: 4 (10): 828-841.
7. Zaenglein AL, Thiboutot DM,. Expert committee recommendations for acne management. Pediatrics 2006: 118 (3): 1188-1199.
8. Leyden JJ, Preston N, Osborn C, Gottschalk RW,. In-vivo effectiveness of adapalene 0.1%/benzoyl peroxide 2.5% gel on antibiotic-sensitive and resistant Propionibacterium acnes. J Clin Aesthet Dermatol 2011: 4 (5): 22-26.
9. Baldwin HE,. A community-based study of the effectiveness of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) on quality of life and satisfaction with treatment in participants with rosacea. Cutis 2011: 86 (5 Suppl.): 26-36.
10. Pfeffer I, Borelli C, Zierhut M, Schaller M,. Treatment of ocular rosacea with 40 mg doxycycline in a slow release form. J Dtsch Dermatol Ges 2011: 9 (11): 904-907.
11. Dreno B, Reynaud A, Moyse D, Habert H, Richet H,. Erythromycin-resistance of cutaneous bacterial flora in acne. Eur J Dermatol 2001: 11 (6): 549-553.
12. Eady EA, Gloor M, Leyden JJ,. Propionibacterium acnes resistance: a worldwide problem. Dermatology 2003: 206 (1): 54-56.
13. Harkaway KS, McGinley KJ, Foglia AN, et al,. Antibiotic resistance patterns in coagulase-negative staphylococci after treatment with topical erythromycin, benzoyl peroxide, and combination therapy. Br J Dermatol 1992: 126 (6): 586-590.
14. Eady EA, Farmery MR, Ross JI, Cove JH, Cunliffe WJ,. Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic-sensitive and -resistant skin bacteria from acne patients. Br J Dermatol 1994: 131 (3): 331-336.
15. Eady EA, Bojar RA, Jones CE, Cove JH, Holland KT, Cunliffe WJ,. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Br J Dermatol 1996: 134 (1): 107-113.
16. Fridkin SK, Hageman JC, Morrison M, et al,. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005: 352 (14): 1436-1444.
17. Seybold U, Kourbatova EV, Johnson JG, et al,. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006: 42 (5): 647-656.
18. Hebert AA, Still JG, Reuman PD,. Comparative safety and efficacy of clarithromycin and cefadroxil suspensions in the treatment of mild to moderate skin and skin structure infections in children. Pediatr Infect Dis J 1993: 12 (12 Suppl. 3): S112-S117.
19. Montero L,. A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin and/or soft tissue infections. J Antimicrob Chemother 1996: 37 (Suppl. C): 125-131.
20. Langner A, Chu A, Goulden V, Ambroziak M,. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. Br J Dermatol 2008: 158 (1): 122-129.
21. Langner A, Sheehan-Dare R, Layton A,. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris. J Eur Acad Dermatol Venereol 2007: 21 (3): 311-319.
22. Leyden J, Kaidbey K, Levy SF,. The combination formulation of clindamycin 1% plus benzoyl peroxide 5% versus 3 different formulations of topical clindamycin alone in the reduction of Propionibacterium acnes. An in vivo comparative study. Am J Clin Dermatol 2001: 2 (4): 263-266.
23. Leyden JJ, Hickman JG, Jarratt MT, Stewart DM, Levy SF,. The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J Cutan Med Surg 2001: 5 (1): 37-42.
24. Qin X, Poon B, Kwong J, et al,. Two paediatric cases of skin and soft-tissue infections due to clindamycin-resistant Staphylococcus aureus carrying a plasmid-encoded vga(A) allelic variant for a putative efflux pump. Int J Antimicrob Agents 2011: 38 (1): 81-83.
25. Katopodis GD, Grivea IN, Tsantsaridou AJ, Pournaras S, Petinaki E, Syrogiannopoulos GA,. Fusidic acid and clindamycin resistance in community-associated, methicillin-resistant Staphylococcus aureus infections in children of Central Greece. BMC Infect Dis 2010: 10: 351.
26. Chen I, Kaufisi P, Erdem G,. Emergence of erythromycin- and clindamycin-resistant Streptococcus pyogenes emm 90 strains in Hawaii. J Clin Microbiol 2011: 49 (1): 439-441.
27. Jorgensen JH, Crawford SA, McElmeel ML, Fiebelkorn KR,. Detection of inducible clindamycin resistance of staphylococci in conjunction with performance of automated broth susceptibility testing. J Clin Microbiol 2004: 42 (4): 1800-1802.
28. Rosen T,. Antibiotic resistance: an editorial review with recommendations. J Drugs Dermatol 2011: 10 (7): 724-733.
29. Bradley SF,. MRSA colonisation (eradicating colonisation in people without active/invasive infection). Clin Evid (Online) 2011: 1: 923.
30. Bradley SF, Ramsey MA, Morton TM, Kauffman CA,. Mupirocin resistance: clinical and molecular epidemiology. Infect Control Hosp Epidemiol 1995: 16 (6): 354-358.
31. McConeghy KW, Mikolich DJ, LaPlante KL,. Agents for the decolonization of methicillin-resistant Staphylococcus aureus. Pharmacotherapy 2009: 29 (3): 263-280.
32. Kluytmans J, van Belkum A, Verbrugh H,. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997: 10 (3): 505-520.
33. Semret M, Miller MA,. Topical mupirocin for eradication of MRSA colonization with mupirocin-resistant strains. Infect Control Hosp Epidemiol 2001: 22 (9): 578-580.
34. Trautmann M, Stecher J, Hemmer W, Luz K, Panknin HT,. Intranasal mupirocin prophylaxis in elective surgery. A review of published studies. Chemotherapy 2008: 54 (1): 9-16.
35. Watanakunakorn C, Axelson C, Bota B, Stahl C,. Mupirocin ointment with and without chlorhexidine baths in the eradication of Staphylococcus aureus nasal carriage in nursing home residents. Am J Infect Control 1995: 23 (5): 306-309.
36. Laupland KB, Conly JM,. Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review. Clin Infect Dis 2003: 37 (7): 933-938.
37. Liu C, Bayer A, Cosgrove SE, et al,. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011: 52 (3): 285-292.
38. Stevens DL, Bisno AL, Chambers HF, et al,. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005: 41 (10): 1373-1406.
39. Fitch MT, Manthey DE, McGinnis HD, Nicks BA, Pariyadath M,. Videos in clinical medicine. Abscess incision and drainage. N Engl J Med 2007: 357 (19): e20.
40. Rajendran PM, Young D, Maurer T, et al,. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2007: 51 (11): 4044-4048.
41. Gorwitz RJ, Jernigan DB, Powers JH, Jernigan JA, and Participants in the CDC Convened Experts' Meeting on Management of MRSA in the Community. Strategies for clinical management of MRSA in the community: Summary of an experts' meeting convened by the Centers for Disease Control and Prevention. 2006. Available at.
42. Deleo FR, Otto M, Kreiswirth BN, Chambers HF,. Community-associated meticillin-resistant Staphylococcus aureus. Lancet 2010: 375 (9725): 1557-1568.
43. Moran GJ, Krishnadasan A, Gorwitz RJ, et al,. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006: 355 (7): 666-674.
44. Naimi TS, LeDell KH, Como-Sabetti K, et al,. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003: 290 (22): 2976-2984.
45. Cenizal MJ, Skiest D, Luber S, et al,. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007: 51 (7): 2628-2630.
46. Szumowski JD, Cohen DE, Kanaya F, Mayer KH,. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 2007: 51 (2): 423-428.
47. Burchall JJ,. Mechanism of action of trimethoprim-sulfamethoxazole. II. J Infect Dis 1973: 128 (Suppl.): 437-441.
48. Wickersham R, Novak K,. Drug facts and comparisons, Vol. 60. St. Louis, MO: Wolter Kluwers, 2006.
49. MacDougall C,. Chapter 55. Protein Synthesis Inhibitors and Miscellaneous Antibacterial Agents. In:, Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw-Hill, 2011.
50. Tenover FC, McDougal LK, Goering RV, et al,. Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J Clin Microbiol 2006: 44 (1): 108-118.
51. Bismuth R, Zilhao R, Sakamoto H, Guesdon JL, Courvalin P,. Gene heterogeneity for tetracycline resistance in Staphylococcus spp. Antimicrob Agents Chemother 1990: 34 (8): 1611-1614.
52. Schwartz BS, Graber CJ, Diep BA, Basuino L, Perdreau-Remington F, Chambers HF,. Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300. Clin Infect Dis 2009: 48 (10): 1483-1484.
53. Raveh D, Rabinowitz B, Breuer GS, Rudensky B, Yinnon AM,. Risk factors for Clostridium difficile toxin-positive nosocomial diarrhoea. Int J Antimicrob Agents 2006: 28 (3): 231-237.
54. Hyun DY, Mason EO, Forbes A, Kaplan SL,. Trimethoprim-sulfamethoxazole or clindamycin for treatment of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J 2009: 28 (1): 57-59.
55. Purcell K, Fergie J,. Epidemic of community-acquired methicillin- resistant Staphylococcus aureus infections: a 14-year study at Driscoll Children's Hospital. Arch Pediatr Adolesc Med 2005: 159 (10): 980-985.
56. Kaplan SL,. Treatment of community-associated methicillin-resistant Staphylococcus aureus infections. Pediatr Infect Dis J 2005: 24 (5): 457-458.
57. Laibl VR, Sheffield JS, Roberts S, McIntire DD, Trevino S, Wendel GD, Jr,. Clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus in pregnancy. Obstet Gynecol 2005: 106 (3): 461-465.
58. Miller LG, Quan C, Shay A, et al,. A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection. Clin Infect Dis 2007: 44 (4): 483-492.
59. Casewell MW, Hill RL,. In-vitro activity of mupirocin ("pseudomonic acid") against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 1985: 15 (5): 523-531.
60. Capobianco JO, Doran CC, Goldman RC,. Mechanism of mupirocin transport into sensitive and resistant bacteria. Antimicrob Agents Chemother 1989: 33 (2): 156-163.
61. Baird D, Coia J,. Mupirocin-resistant Staphylococcus aureus. Lancet 1987: 2 (8555): 387-388.
62. Goldfarb J, Crenshaw D, O'Horo J, Lemon E, Blumer JL,. Randomized clinical trial of topical mupirocin versus oral erythromycin for impetigo. Antimicrob Agents Chemother 1988: 32 (12): 1780-1783.
63. Miller MA, Dascal A, Portnoy J, Mendelson J,. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol 1996: 17 (12): 811-813.
64. Kauffman CA, Terpenning MS, He X, et al,. Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long-term-care facility with the use of mupirocin ointment. Am J Med 1993: 94 (4): 371-378.
65. Rossney AS, Keane CT,. Strain variation in the MRSA population over a 10-year period in one Dublin hospital. Eur J Clin Microbiol Infect Dis. 2002: 21 (2): 123-126.
66. Perez-Roth E, Claverie-Martin F, Batista N, Moreno A, Mendez-Alvarez S,. Mupirocin resistance in methicillin-resistant Staphylococcus aureus clinical isolates in a Spanish hospital. Co-application of multiplex PCR assay and conventional microbiology methods. Diagn Microbiol Infect Dis 2002: 43 (2): 123-128.
67. Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Falcon TG, Valdes F,. Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 2002: 39 (2): 337-341.
68. Jones JC, Rogers TJ, Brookmeyer P, et al,. Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. Clin Infect Dis 2007: 45 (5): 541-547.
69. Gelmetti C,. Local antibiotics in dermatology. Dermatol Ther 2008: 21 (3): 187-195.
70. Gehrig KA, Warshaw EM,. Allergic contact dermatitis to topical antibiotics: epidemiology, responsible allergens, and management. J Am Acad Dermatol 2008: 58 (1): 1-21.
71. Doebbeling BN, Breneman DL, Neu HC, et al,. Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. The Mupirocin Collaborative Study Group. Clin Infect Dis 1993: 17 (3): 466-474.
72. Soto NE, Vaghjimal A, Stahl-Avicolli A, Protic JR, Lutwick LI, Chapnick EK,. Bacitracin versus mupirocin for Staphylococcus aureus nasal colonization. Infect Control Hosp Epidemiol 1999: 20 (5): 351-353.
73. Raz R, Miron D, Colodner R, Staler Z, Samara Z, Keness Y,. A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection. Arch Intern Med 1996: 156 (10): 1109-1112.
74. Boyce JM,. MRSA patients: proven methods to treat colonization and infection. J Hosp Infect 2001: 48 (Suppl. A): S9-14.
75. Miller LG, Tan J, Eells SJ, Benitez E, Radner AB,. Prospective investigation of nasal mupirocin, hexachlorophene body wash, and systemic antibiotics for prevention of recurrent community-associated methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother 2011: 56 (2): 1084-1086.
76. Robotham JV, Graves N, Cookson BD, et al,. Screening, isolation, and decolonisation strategies in the control of meticillin resistant Staphylococcus aureus in intensive care units: cost effectiveness evaluation. BMJ 2011: 343: d5694.
77. Lee AS, Macedo-Vinas M, Francois P, et al,. Trends in mupirocin resistance in meticillin-resistant Staphylococcus aureus and mupirocin consumption at a tertiary care hospital. J Hosp Infect 2011: 77 (4): 360-362.
78. Cohen PR, Kurzrock R,. Community-acquired methicillin-resistant Staphylococcus aureus skin infection: an emerging clinical problem. J Am Acad Dermatol 2004: 50 (2): 277-280.
79. Lee NE, Taylor MM, Bancroft E, et al,. Risk factors for community-associated methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who have sex with men. Clin Infect Dis 2005: 40 (10): 1529-1534.
80. Adam HJ, Allen VG, Currie A, et al,. Community-associated methicillin-resistant Staphylococcus aureus: prevalence in skin and soft tissue infections at emergency departments in the Greater Toronto Area and associated risk factors. CJEM 2009: 11 (5): 439-446.
81. Eron LJ, Lipsky BA, Low DE, Nathwani D, Tice AD, Volturo GA,. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 2003: 52 (Suppl. 1): i3-17.
82. Elliott DJ, Zaoutis TE, Troxel AB, Loh A, Keren R,. Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus. Pediatrics 2009: 123 (6): e959-e966.
83. Koning S, Verhagen AP, van Suijlekom-Smit LW, Morris A, Butler CC, van der Wouden JC,. Interventions for impetigo. Cochrane Database Syst Rev 2004: (2): CD003261.
84. Sladden MJ, Johnston GA,. Common skin infections in children. BMJ 2004: 329 (7457): 95-99.
85. Koning S, van der Wouden JC, Chosidow O, et al,. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial. Br J Dermatol 2008: 158 (5): 1077-1082.
86. Oranje AP, Chosidow O, Sacchidanand S, et al,. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study. Dermatology 2007: 215 (4): 331-340.
87. Parish LC, Jorizzo JL, Breton JJ, et al,. Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized controlled trial. J Am Acad Dermatol 2006: 55 (6): 1003-1013.
88. Rodriguez-Solares A, Perez-Gutierrez F, Prosperi J, Milgram E, Martin A,. A comparative study of the efficacy, safety and tolerance of azithromycin, dicloxacillin and flucloxacillin in the treatment of children with acute skin and skin-structure infections. J Antimicrob Chemother 1993: 31 (Suppl. E): 103-109.
89. Blaszcyk-Kostanecka M, Dobozy A, Dominguez-Soto L, Guerrero R, Hunyadi J, Lopera J,. Comparision of two regimens of oral clindamycin versus dicloxacillin in the treatment of mild to moderate skin and soft tissue infections. Curr Ther Res Clin Exp 1998: 59: 341-353.
90. Iyer S, Jones DH,. Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak. J Am Acad Dermatol 2004: 50 (6): 854-858.
91. Moran GJ, Amii RN, Abrahamian FM, Methicillin-resistant TDA,. Staphylococcus aureus in community-acquired skin infections. Emerg Infect Dis 2005: 11 (6): 928-930.
92. Fung HB, Kirschenbaum HL, Ojofeitimi BO,. Linezolid: an oxazolidinone antimicrobial agent. Clin Ther 2001: 23 (3): 356-391.
93. Moise PA, Sakoulas G,. Staphylococcus aureus: resistance update and treatment options. In:, Owens RC, Lautenbach E, eds. Antimicrobial resistance: problem pathogens and clinical countermeasures, Vol. 48. New York: Informa Healthcare, USA, 2007: 75-88.
94. Breedt J, Teras J, Gardovskis J, et al,. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005: 49 (11): 4658-4666.
95. Failla DM, Pankey GA,. Optimum outpatient therapy of skin and skin structure infections. Drugs 1994: 48 (2): 172-178.
96. Yu Y, Cheng AS, Wang L, Dunne WM, Bayliss SJ,. Hot tub folliculitis or hot hand-foot syndrome caused by Pseudomonas aeruginosa. J Am Acad Dermatol 2007: 57 (4): 596-600.
97. Lutz JK, Lee J,. Prevalence and antimicrobial-resistance of Pseudomonas aeruginosa in swimming pools and hot tubs. Int J Environ Res Public Health 2011: 8 (2): 554-564.
98. Gupta AK, Batra R, Bluhm R, Boekhout T, Dawson TL, Jr,. Skin diseases associated with Malassezia species. J Am Acad Dermatol 2004: 51 (5): 785-798.
99. Lee JW, Lee HI, Kim MN, Kim BJ, Chun YJ, Kim D,. Topical photodynamic therapy with methyl aminolevulinate may be an alternative therapeutic option for the recalcitrant Malassezia folliculitis. Int J Dermatol 2011: 50 (4): 488-490.
100. Zeglaoui F, Dziri C, Mokhtar I, et al,. Intramuscular bipenicillin vs. intravenous penicillin in the treatment of erysipelas in adults: randomized controlled study. J Eur Acad Dermatol Venereol 2004: 18 (4): 426-428.
101. Fleisher GR, Wilmott CM, Campos JM,. Amoxicillin combined with clavulanic acid for the treatment of soft tissue infections in children. Antimicrob Agents Chemother 1983: 24 (5): 679-681.
102. Jorup-Ronstrom C, Britton S, Gavlevik A, Gunnarsson K, Redman AC,. The course, costs and complications of oral versus intravenous penicillin therapy of erysipelas. Infection 1984: 12 (6): 390-394.
103. Aly AA, Roberts NM, Seipol KS, MacLellan DG,. Case survey of management of cellulitis in a tertiary teaching hospital. Med J Aust 1996: 165 (10): 553-556.
104. Krasagakis K, Valachis A, Maniatakis P, Kruger-Krasagakis S, Samonis G, Tosca AD,. Analysis of epidemiology, clinical features and management of erysipelas. Int J Dermatol 2010: 49 (9): 1012-1017.
105. Gabillot-Carre M, Roujeau JC,. Acute bacterial skin infections and cellulitis. Curr Opin Infect Dis 2007: 20 (2): 118-123.
106. Eckmann C, Dryden M,. Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin. Eur J Med Res 2010: 15 (12): 554-563.
107. Chiang-Ni C, Zheng PX, Ho YR, et al,. emm1/sequence type 28 strains of group A streptococci that express covR at early stationary phase are associated with increased growth and earlier SpeB secretion. J Clin Microbiol 2009: 47 (10): 3161-3169.
108. Plainvert C, Doloy A, Loubinoux J, Lepoutre A, Collobert G, Touak G, Trieu-Cuot P, Bouvet A, Poyart C, and on behalf of the CNR-Strep network. Invasive group A streptococcal infections in adults, France (2006-2010). Clin Microbiol Infect 2011; doi: 10.1111/j.1469-0691.2011.03624.x.
109. French N, Modlin RL,. Bacterial and mycobacterial infections. In:, Krieg T, Bickers DR, Miyachi Y, eds. Therapy of skin diseases: a worldwide perspective on therapeutic approaches and their molecular basis. Berlin: Springer, 2010: 129-148.
110. Lowney ED, Baublis JV, Kreye GM, Harrell ER, McKenzie AR,. The scalded skin syndrome in small children. Arch Dermatol 1967: 95 (4): 359-369.
111. Patel GK, Finlay AY,. Staphylococcal scalded skin syndrome: diagnosis and management. Am J Clin Dermatol 2003: 4 (3): 165-175.
112. Bailey CJ, Lockhart BP, Redpath MB, Smith TP,. The epidermolytic (exfoliative) toxins of Staphylococcus aureus. Med Microbiol Immunol (Berl) 1995: 184 (2): 53-61.
113. Ruocco E, Baroni A, Sangiuliano S, Donnarumma G, Ruocco V,. Staphylococcal Scalded Skin Syndrome. In:, Wolf R, Davidovici BB, Parish JL, Raish LC, eds. Emergency dermatology. Cambridge: Cambridge University Press, 2010: 109-114.
114. Amagai M, Matsuyoshi N, Wang ZH, Andl C, Stanley JR,. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nat Med 2000: 6 (11): 1275-1277.
115. Amagai M, Yamaguchi T, Hanakawa Y, Nishifuji K, Sugai M, Stanley JR,. Staphylococcal exfoliative toxin B specifically cleaves desmoglein 1. J Invest Dermatol 2002: 118 (5): 845-850.
116. Yokota S, Imagawa T, Katakura S, Mitsuda T, Arai K,. Staphylococcal scalded skin syndrome caused by exfoliative toxin B-producing methicillin-resistant Staphylococcus aureus. Eur J Pediatr 1996: 155 (8): 722.
117. Acland KM, Darvay A, Griffin C, Aali SA, Russell-Jones R,. Staphylococcal scalded skin syndrome in an adult associated with methicillin-resistant Staphylococcus aureus. Br J Dermatol 1999: 140 (3): 518-520.
118. Centers for Disease Control and Prevention. Cephalosporin susceptibility among Neisseria gonorrhoeae isolates-United States, 2000-2010. MMWR Morb Mortal Wkly Rep 2011: 60 (26): 873-877.
119. Dancer SJ, Simmons NA, Poston SM, Noble WC,. Outbreak of staphylococcal scalded skin syndrome among neonates. J Infect 1988: 16 (1): 87-103.
120. Chi CY, Wang SM, Lin HC, Liu CC,. A clinical and microbiological comparison of Staphylococcus aureus toxic shock and scalded skin syndromes in children. Clin Infect Dis 2006: 42 (2): 181-185.
121. Centers for Disease Control and Prevention. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 2011: 60: 1650-1653.
122. Jensen PA, Lambert LA, Iademarco MF, Ridzon R,. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 2005: 54 (RR-17): 1-141.
123. Borrell S, Gagneux S,. Strain diversity, epistasis and the evolution of drug resistance in Mycobacterium tuberculosis. Clin Microbiol Infect 2011: 17 (6): 815-820.
124. Sougakoff W,. Molecular epidemiology of multidrug-resistant strains of Mycobacterium tuberculosis. Clin Microbiol Infect 2011: 17 (6): 800-805.
125. Mahmoudi A, Iseman MD,. Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance. JAMA 1993: 270 (1): 65-68.
126. Kochi A, Vareldzis B, Styblo K,. Multidrug-resistant tuberculosis and its control. Res Microbiol 1993: 144 (2): 104-110.
127. Davies PDO, Cooke R,. Mycobacterial antimicribial resistance. In:, Fong IW, Drlica K, eds. Antimicrobial resistance and implications for the 21st century. New York: Springer, 2008: 161-205.
128. A controlled trial of a 2-month, 3-month, and 12-month regimens of chemotherapy for sputum smear-negative pulmonary tuberculosis: the results at 30 months. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis 1981: 124 (2): 138-142.
129. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis 1987: 136 (6): 1339-1342.
130. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis 1991: 143 (4 Pt 1): 700-706.
131. Blumberg HM, Burman WJ, Chaisson RE, et al,. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003: 167 (4): 603-662.
132. Dorman SE, Johnson JL, Goldberg S, et al,. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009: 180 (3): 273-280.
133. Hu Y, Coates AR, Mitchison DA,. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003: 47 (2): 653-657.
134. Gosling RD, Uiso LO, Sam NE, et al,. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003: 168 (11): 1342-1345.
135. Workowski KA, Berman SM,. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006: 55 (RR-11): 1-94.
136. Rekart M, Patrick D, Jolly A, et al,. Mass treatment/prophylaxis during an outbreak of infectious syphilis in Vancouver, British Columbia. Can Commun Dis Rep 2000: 26 (12): 101-105.
137. Hook EW, 3rd, Martin DH, Stephens J, Smith BS, Smith K,. A randomized, comparative pilot study of azithromycin versus benzathine penicillin G for treatment of early syphilis. Sex Transm Dis 2002: 29 (8): 486-490.
138. Stamm LV, Greene SR, Bergen HL, Hardham JM, Barnes NY,. Identification and sequence analysis of Treponema pallidum tprJ, a member of a polymorphic multigene family. FEMS Microbiol Lett 1998: 169 (1): 155-163.
139. Lukehart SA, Godornes C, Molini BJ, et al,. Macrolide resistance in Treponema pallidum in the United States and Ireland. N Engl J Med 2004: 351 (2): 154-158.
140. Ison CA, Alexander S,. Antimicrobial resistance in Neisseria gonorrhoeae in the UK: surveillance and management. Expert Rev Anti Infect Ther 2011: 9 (10): 867-876.
141. Antimicrobial resistance in gonococci, WHO Western Pacific Region, 1996. The WHO Western Pacific Region Gonococcal Antimicrobial Surveillance Programme. Commun Dis Intell 1997: 21 (23): 349-353.
142. Solomon AW, Mohammed Z, Massae PA, et al,. Impact of mass distribution of azithromycin on the antibiotic susceptibilities of ocular Chlamydia trachomatis. Antimicrob Agents Chemother 2005: 49 (11): 4804-4806.
143. Bong CT, Bauer ME, Spinola SM,. Haemophilus ducreyi: clinical features, epidemiology, and prospects for disease control. Microbes Infect 2002: 4 (11): 1141-1148.
144. Ballard RC, Duncan MO, Fehler HG, Dangor Y, Exposto FL, Latif AS,. Treating chancroid: summary of studies in southern Africa. Genitourin Med 1989: 65 (1): 54-57.
145. Rutanarugsa A, Vorachit M, Polnikorn N, Jayanetra P,. Drug resistance of Haemophilus ducreyi. Southeast Asian J Trop Med Public Health 1990: 21 (2): 185-193.
146. Bilgeri YR, Ballard RC, Duncan MO, Mauff AC, Koornhof HJ,. Antimicrobial susceptibility of 103 strains of Haemophilus ducreyi isolated in Johannesburg. Antimicrob Agents Chemother 1982: 22 (4): 686-688.